160 related articles for article (PubMed ID: 20798699)
21. Progress in the treatment of multiple myeloma.
Kumar S
Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
[No Abstract] [Full Text] [Related]
22. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Kebriaei P; Madden T; Kazerooni R; Wang X; Thall PF; Ledesma C; Nieto Y; Shpall EJ; Hosing C; Qazilbash M; Popat U; Khouri I; Champlin RE; Jones RB; Andersson BS
Biol Blood Marrow Transplant; 2011 Mar; 17(3):412-20. PubMed ID: 20674757
[TBL] [Abstract][Full Text] [Related]
23. Optimising bortezomib in newly diagnosed multiple myeloma.
Rajkumar SV
Lancet Oncol; 2010 Oct; 11(10):909-10. PubMed ID: 20739219
[No Abstract] [Full Text] [Related]
24. Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Borad MJ; Swift R; Berenson JR
Leukemia; 2005 Jan; 19(1):154-6. PubMed ID: 15496977
[No Abstract] [Full Text] [Related]
25. A new standard of care for elderly patients with myeloma.
Palumbo A; Boccadoro M
Lancet; 2007 Oct; 370(9594):1191-2. PubMed ID: 17920906
[No Abstract] [Full Text] [Related]
26. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.
Moreau P; Facon T; Attal M; Hulin C; Michallet M; Maloisel F; Sotto JJ; Guilhot F; Marit G; Doyen C; Jaubert J; Fuzibet JG; François S; Benboubker L; Monconduit M; Voillat L; Macro M; Berthou C; Dorvaux V; Pignon B; Rio B; Matthes T; Casassus P; Caillot D; Najman N; Grosbois B; Bataille R; Harousseau JL;
Blood; 2002 Feb; 99(3):731-5. PubMed ID: 11806971
[TBL] [Abstract][Full Text] [Related]
27. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
28. Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients.
Chretien ML; Hebraud B; Cances-Lauwers V; Hulin C; Marit G; Leleu X; Karlin L; Roussel M; Stoppa AM; Guilhot F; Lamy T; Garderet L; Pegourie B; Dib M; Sebban C; Lenain P; Brechignac S; Royer B; Wetterwald M; Legros L; Orsini-Piocelle F; Voillat L; Delbrel X; Caillot D; Macro M; Facon T; Attal M; Moreau P; Avet-Loiseau H; Corre J
Haematologica; 2014 Jul; 99(7):1236-8. PubMed ID: 24727820
[TBL] [Abstract][Full Text] [Related]
29. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
[TBL] [Abstract][Full Text] [Related]
30. Hb H disease and multiple myeloma.
Elhajj I; Chehal A; Shamseddine A; Mourad YA; Taher A
Hemoglobin; 2004 Feb; 28(1):79-82. PubMed ID: 15008270
[No Abstract] [Full Text] [Related]
31. Rationale for adjuvant idiotypic vaccination after high-dose therapy for multiple myeloma.
Reichardt VL; Okada CY; Stockerl-Goldstein KE; Bogen B; Levy R
Biol Blood Marrow Transplant; 1997 Aug; 3(3):157-63. PubMed ID: 9310193
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of minimal residual disease by interphase FISH in multiple myeloma: does complete remission exist?
Genevieve F; Zandecki M; Laï JL; Hennache B; Faucompre JL; Stalnikiewicz L; Bauters F; Facon T
Leukemia; 1999 Apr; 13(4):641-4. PubMed ID: 10214874
[TBL] [Abstract][Full Text] [Related]
33. Melphalan kinetics in hyperthermic isolation perfusion of the extremities.
Loos U; Musch E; Rauschecker H; Willenbrock C
J Chemother; 1989 Jul; 1(4 Suppl):1246-7. PubMed ID: 16312851
[No Abstract] [Full Text] [Related]
34. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.
Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B
J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273
[TBL] [Abstract][Full Text] [Related]
35. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma : recent progress in diagnosis and treatment.
Chou T
J Clin Exp Hematop; 2012; 52(3):149-59. PubMed ID: 23269074
[TBL] [Abstract][Full Text] [Related]
37. Alexanian R, Bergsagel DE, Migliore PJ, Vaughn WK, Howe CD. Melphalan therapy for plasma cell myeloma. Blood. 1968;31(1):1-10.
Blood; 2016 Aug; 128(6):741. PubMed ID: 27516424
[No Abstract] [Full Text] [Related]
38. Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation.
Giralt SA; Mangan KF; Maziarz RT; Bubalo JS; Beveridge R; Hurd DD; Mendoza FL; Rubenstein EB; DeGroot TJ; Schuster MW
Ann Oncol; 2011 Apr; 22(4):939-946. PubMed ID: 20935058
[TBL] [Abstract][Full Text] [Related]
39. Autotransplants in multiple myeloma: what have we learned?
Vesole DH; Tricot G; Jagannath S; Desikan KR; Siegel D; Bracy D; Miller L; Cheson B; Crowley J; Barlogie B
Blood; 1996 Aug; 88(3):838-47. PubMed ID: 8704239
[TBL] [Abstract][Full Text] [Related]
40. A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A; Wiseman GA; Lacy MQ; Litzow MR; Anderson PM; Gastineau DA; Tefferi A; Inwards DJ; Micallef IN; Ansell SM; Porrata L; Elliott MA; Lust JA; Greipp PR; Rajkumar SV; Fonseca R; Witzig TE; Erlichman C; Sloan JA; Gertz MA
Leukemia; 2005 Jan; 19(1):118-25. PubMed ID: 15526021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]